重症监护中静脉血栓栓塞预防的抗Xa水平:系统评价与荟萃分析
该系统评价与荟萃分析检索Medline和Embase至2025年5月7日,纳入39项研究共7124例接受低分子肝素血栓预防的重症成人。接受低分子肝素预防的患者中达到目标抗Xa水平的比例为47%(95%CI 36-57%)。亚预防抗Xa水平与静脉血栓栓塞风险增加相关(uOR 2.87;95%CI 1.42-5.81;低确定性)。男性(aOR 2.65;95%CI 1.07-6.56)、体重增加(较目标水平者高4.90 kg;95%CI 2.78-7.02)和体重指数升高(较目标水平者每kg/m²高1.36;95%CI 0.64-2.09)与亚预防抗Xa水平有中等确定性关联。作者认为该研究凸显了重症成人抗Xa水平监测的临床重要性,并需要未来随机对照试验进一步评估。
要点
- 重症成人低分子肝素血栓预防中仅47%(95%CI 36-57%)达到目标抗Xa水平。
- 亚预防抗Xa水平与静脉血栓栓塞风险增加相关(uOR 2.87;95%CI 1.42-5.81;低确定性)。
- 男性与亚预防抗Xa水平相关(aOR 2.65;95%CI 1.07-6.56;中等确定性)。
- 体重较目标水平者高4.90 kg(95%CI 2.78-7.02)与亚预防抗Xa水平相关(中等确定性)。
- 体重指数较目标水平者每高1 kg/m²(MD 1.36;95%CI 0.64-2.09)与亚预防抗Xa水平相关(中等确定性)。
适用人群与场景
- 接受低分子肝素血栓预防的重症成人。
研究设计与关键结果
- 系统评价与荟萃分析,纳入39项研究共7124例患者。
- 接受低分子肝素预防的患者中达到目标抗Xa水平的比例为47%(95%CI 36-57%)。
- 亚预防抗Xa水平与静脉血栓栓塞风险增加相关(uOR 2.87;95%CI 1.42-5.81;低确定性)。
- 男性与亚预防抗Xa水平相关(aOR 2.65;95%CI 1.07-6.56;中等确定性)。
- 体重较目标水平者高4.90 kg(95%CI 2.78-7.02)与亚预防抗Xa水平相关(中等确定性)。
- 体重指数较目标水平者每高1 kg/m²(MD 1.36;95%CI 0.64-2.09)与亚预防抗Xa水平相关(中等确定性)。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析,采用GRADE方法评估证据确定性。
- 亚预防抗Xa水平与静脉血栓栓塞风险的关联为低确定性。
- 男性、体重增加和体重指数升高与亚预防抗Xa水平的关联为中等确定性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为该研究凸显了重症成人抗Xa水平监测的临床重要性。
- 作者认为需要未来随机对照试验进一步评估该主题。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the relationships between subprophylactic anti-Xa levels and low-molecular-weight heparin (LMWH) thromboprophylaxis regimens with venous thromboembolism (VTE) risk, and to identify predictors of subprophylactic anti-Xa levels in critically ill adults.
DATA SOURCES: Medline and Embase were searched from inception to May 7, 2025.
STUDY SELECTION: We included studies enrolling critically ill adults receiving LMWH thromboprophylaxis and assessing the relationship between anti-Xa levels and risk of subprophylactic measurements associated with: 1) standard dosing strategies; 2) VTE risk; or 3) predisposing factors.
DATA EXTRACTION: We extracted or calculated mean, sd , median, interquartile range, mean difference (MD), unadjusted odds ratios (uORs), and adjusted odds ratios (aORs), when available. Risk of bias was evaluated using Cochrane tools. We assessed certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluation approach.
DATA SYNTHESIS: We included 39 studies (7124 patients). The proportion of patients receiving LMWH prophylaxis achieving target anti-Xa levels was 47% (95% CI, 36-57%). Subprophylactic anti-Xa levels were associated with an increased risk of VTE (uOR, 2.87; 95% CI, 1.42-5.81; low certainty). Variables with a moderate certainty association with subprophylactic anti-Xa levels include male sex (aOR, 2.65; 95% CI, 1.07-6.56), increased weight (MD, 4.90 kg higher weight compared with those with target levels; 95% CI, 2.78-7.02), and elevated body mass index (MD, 1.36 per kg/m 2 higher compared with those with target levels; 95% CI, 0.64-2.09).
CONCLUSIONS: Less than half of critically ill patients achieved their prophylactic anti-Xa targets despite LMWH thromboprophylaxis. Subprophylactic anti-Xa levels may be associated with an increased risk of VTE. Male sex, increased weight, and elevated body mass index have a moderate certainty association with developing subprophylactic anti-Xa levels. This study highlights the clinical importance of anti-Xa level monitoring in critically ill adults and the need for a future randomized controlled trial to further evaluate this topic.
参考来源
- Durr KM, Ehlebracht A, Rochwerg B, et al. Anti-Xa Levels With Venous Thromboembolism Prophylaxis in Critical Care: A Systematic Review and Meta-Analysis. Crit Care Med. 2026. PMID: 41811030. doi:10.1097/CCM.0000000000007079
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。